Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.79
BCR's Cash to Debt is ranked lower than
58% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.41 vs. BCR: 0.79 )
Ranked among companies with meaningful Cash to Debt only.
BCR' s 10-Year Cash to Debt Range
Min: 0.06  Med: 0.81 Max: 4.9
Current: 0.79
0.06
4.9
Equity to Asset 0.33
BCR's Equity to Asset is ranked lower than
85% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. BCR: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
BCR' s 10-Year Equity to Asset Range
Min: 0.33  Med: 0.56 Max: 0.77
Current: 0.33
0.33
0.77
Interest Coverage 17.44
BCR's Interest Coverage is ranked lower than
60% of the 105 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.02 vs. BCR: 17.44 )
Ranked among companies with meaningful Interest Coverage only.
BCR' s 10-Year Interest Coverage Range
Min: 5  Med: 19.67 Max: 60.49
Current: 17.44
5
60.49
F-Score: 6
Z-Score: 3.94
M-Score: -2.86
WACC vs ROIC
2.25%
12.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 24.91
BCR's Operating margin (%) is ranked higher than
92% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.42 vs. BCR: 24.91 )
Ranked among companies with meaningful Operating margin (%) only.
BCR' s 10-Year Operating margin (%) Range
Min: 13.55  Med: 21.53 Max: 28.28
Current: 24.91
13.55
28.28
Net-margin (%) 10.38
BCR's Net-margin (%) is ranked higher than
72% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.58 vs. BCR: 10.38 )
Ranked among companies with meaningful Net-margin (%) only.
BCR' s 10-Year Net-margin (%) Range
Min: 5.96  Med: 12.96 Max: 22.62
Current: 10.38
5.96
22.62
ROE (%) 20.10
BCR's ROE (%) is ranked higher than
89% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.05 vs. BCR: 20.10 )
Ranked among companies with meaningful ROE (%) only.
BCR' s 10-Year ROE (%) Range
Min: 12.31  Med: 20.68 Max: 44.24
Current: 20.1
12.31
44.24
ROA (%) 6.92
BCR's ROA (%) is ranked higher than
70% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. BCR: 6.92 )
Ranked among companies with meaningful ROA (%) only.
BCR' s 10-Year ROA (%) Range
Min: 5.54  Med: 12.09 Max: 21.39
Current: 6.92
5.54
21.39
ROC (Joel Greenblatt) (%) 72.66
BCR's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.82 vs. BCR: 72.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BCR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.58  Med: 80.81 Max: 148.85
Current: 72.66
25.58
148.85
Revenue Growth (3Y)(%) 9.10
BCR's Revenue Growth (3Y)(%) is ranked higher than
74% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. BCR: 9.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BCR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5  Med: 10.20 Max: 13.9
Current: 9.1
-1.5
13.9
EBITDA Growth (3Y)(%) 4.30
BCR's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. BCR: 4.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BCR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -18.5  Med: 11.80 Max: 41
Current: 4.3
-18.5
41
EPS Growth (3Y)(%) 0.50
BCR's EPS Growth (3Y)(%) is ranked lower than
60% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. BCR: 0.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BCR' s 10-Year EPS Growth (3Y)(%) Range
Min: -14.8  Med: 12.10 Max: 43.2
Current: 0.5
-14.8
43.2
» BCR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

BCR Guru Trades in Q3 2014

John Hussman 15,000 sh (New)
Joel Greenblatt 229,325 sh (+470.83%)
Ray Dalio 59,086 sh (+115.75%)
Jim Simons 542,100 sh (+29.63%)
Pioneer Investments 962,724 sh (unchged)
Louis Moore Bacon Sold Out
Jeremy Grantham 211,694 sh (-0.33%)
Yacktman Fund 3,250,000 sh (-2.40%)
Donald Yacktman 6,443,334 sh (-3.85%)
Yacktman Focused Fund 2,150,000 sh (-6.52%)
Vanguard Health Care Fund 1,039,100 sh (-10.22%)
Robert Olstein 34,000 sh (-10.53%)
Paul Tudor Jones 3,890 sh (-13.56%)
» More
Q4 2014

BCR Guru Trades in Q4 2014

Paul Tudor Jones 33,366 sh (+757.74%)
Jim Simons 898,900 sh (+65.82%)
Jeremy Grantham 259,364 sh (+22.52%)
Donald Yacktman 4,455,796 sh (unchged)
Robert Olstein Sold Out
Pioneer Investments 961,981 sh (-0.08%)
Vanguard Health Care Fund 912,700 sh (-12.16%)
Ray Dalio 47,138 sh (-20.22%)
Yacktman Focused Fund 1,614,000 sh (-24.93%)
Donald Yacktman 4,455,796 sh (-30.85%)
John Hussman 10,000 sh (-33.33%)
Yacktman Fund 2,096,000 sh (-35.51%)
Joel Greenblatt 14,178 sh (-93.82%)
» More
Q1 2015

BCR Guru Trades in Q1 2015

Louis Moore Bacon 37,500 sh (New)
Steven Cohen 273,500 sh (New)
Paul Tudor Jones 151,300 sh (+353.46%)
Joel Greenblatt 44,492 sh (+213.81%)
Jim Simons 1,112,900 sh (+23.81%)
Pioneer Investments 964,349 sh (+0.25%)
Vanguard Health Care Fund 912,700 sh (unchged)
John Hussman 10,000 sh (unchged)
Ray Dalio Sold Out
Jeremy Grantham 225,921 sh (-12.89%)
Yacktman Focused Fund 1,220,000 sh (-24.41%)
Yacktman Fund 1,570,000 sh (-25.10%)
Donald Yacktman 3,326,670 sh (-25.34%)
» More
Q2 2015

BCR Guru Trades in Q2 2015

John Hussman 10,000 sh (unchged)
Vanguard Health Care Fund 912,700 sh (unchged)
Yacktman Fund 1,350,000 sh (-14.01%)
Yacktman Focused Fund 950,000 sh (-22.13%)
» More
» Details

Insider Trades

Latest Guru Trades with BCR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on CR Bard Inc

Yacktman Funds Comments on C.R. Bard Inc. - Mar 12, 2014

During the fourth quarter, C.R. Bard Inc’s shares rose sharply as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years.



From Yacktman Funds' 2013 Annual Report - Portfolio Manager's Comments



Check out Donald Yacktman latest stock trades

Yacktman Fund Comments on C.R. Bard Inc. - Jan 30, 2014

C.R. Bard Inc. (BCR)'s shares rose sharply during the quarter as the company received more than $800 million in pre-tax proceeds from a long-running patent lawsuit victory. The company has already used some of the proceeds to make acquisitions and increase its investments in attractive new technologies. We think C.R. Bard Inc. is positioned to be one of the fastest growing health care companies over the next few years.

From the Yacktman Fund (Trades, Portfolio)s' fourth quarter 2013 shareholder update.

Check out Donald Yacktman latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 37.40
BCR's P/E(ttm) is ranked lower than
61% of the 108 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.20 vs. BCR: 37.40 )
Ranked among companies with meaningful P/E(ttm) only.
BCR' s 10-Year P/E(ttm) Range
Min: 13.82  Med: 22.27 Max: 80.1
Current: 37.4
13.82
80.1
Forward P/E 20.00
BCR's Forward P/E is ranked higher than
62% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.03 vs. BCR: 20.00 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 37.00
BCR's PE(NRI) is ranked lower than
64% of the 110 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.60 vs. BCR: 37.00 )
Ranked among companies with meaningful PE(NRI) only.
BCR' s 10-Year PE(NRI) Range
Min: 13.74  Med: 22.23 Max: 78.13
Current: 37
13.74
78.13
P/B 8.80
BCR's P/B is ranked lower than
88% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.85 vs. BCR: 8.80 )
Ranked among companies with meaningful P/B only.
BCR' s 10-Year P/B Range
Min: 3.22  Med: 4.58 Max: 8.8
Current: 8.8
3.22
8.8
P/S 4.41
BCR's P/S is ranked lower than
61% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.84 vs. BCR: 4.41 )
Ranked among companies with meaningful P/S only.
BCR' s 10-Year P/S Range
Min: 2.55  Med: 3.61 Max: 4.66
Current: 4.41
2.55
4.66
PFCF 19.96
BCR's PFCF is ranked higher than
76% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.29 vs. BCR: 19.96 )
Ranked among companies with meaningful PFCF only.
BCR' s 10-Year PFCF Range
Min: 9.99  Med: 17.57 Max: 47.48
Current: 19.96
9.99
47.48
POCF 16.79
BCR's POCF is ranked higher than
62% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.15 vs. BCR: 16.79 )
Ranked among companies with meaningful POCF only.
BCR' s 10-Year POCF Range
Min: 8.99  Med: 14.92 Max: 26.9
Current: 16.79
8.99
26.9
EV-to-EBIT 23.27
BCR's EV-to-EBIT is ranked lower than
52% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.59 vs. BCR: 23.27 )
Ranked among companies with meaningful EV-to-EBIT only.
BCR' s 10-Year EV-to-EBIT Range
Min: 9.1  Med: 15.50 Max: 19.7
Current: 23.27
9.1
19.7
PEG 4.35
BCR's PEG is ranked lower than
65% of the 65 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. BCR: 4.35 )
Ranked among companies with meaningful PEG only.
BCR' s 10-Year PEG Range
Min: 0.83  Med: 1.46 Max: 33.25
Current: 4.35
0.83
33.25
Shiller P/E 34.25
BCR's Shiller P/E is ranked lower than
53% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.99 vs. BCR: 34.25 )
Ranked among companies with meaningful Shiller P/E only.
BCR' s 10-Year Shiller P/E Range
Min: 19.52  Med: 26.67 Max: 41.87
Current: 34.25
19.52
41.87
Current Ratio 1.96
BCR's Current Ratio is ranked lower than
61% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. BCR: 1.96 )
Ranked among companies with meaningful Current Ratio only.
BCR' s 10-Year Current Ratio Range
Min: 1.14  Med: 2.47 Max: 5.88
Current: 1.96
1.14
5.88
Quick Ratio 1.61
BCR's Quick Ratio is ranked higher than
50% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. BCR: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
BCR' s 10-Year Quick Ratio Range
Min: 0.62  Med: 1.95 Max: 4.72
Current: 1.61
0.62
4.72
Days Inventory 108.46
BCR's Days Inventory is ranked higher than
66% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 129.36 vs. BCR: 108.46 )
Ranked among companies with meaningful Days Inventory only.
BCR' s 10-Year Days Inventory Range
Min: 86.57  Med: 105.04 Max: 172.3
Current: 108.46
86.57
172.3
Days Sales Outstanding 49.04
BCR's Days Sales Outstanding is ranked higher than
76% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.83 vs. BCR: 49.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCR' s 10-Year Days Sales Outstanding Range
Min: 49.99  Med: 61.61 Max: 74.99
Current: 49.04
49.99
74.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.46
BCR's Dividend Yield is ranked lower than
86% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. BCR: 0.46 )
Ranked among companies with meaningful Dividend Yield only.
BCR' s 10-Year Dividend Yield Range
Min: 0.34  Med: 0.72 Max: 0.9
Current: 0.46
0.34
0.9
Dividend Payout 0.19
BCR's Dividend Payout is ranked higher than
86% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.36 vs. BCR: 0.19 )
Ranked among companies with meaningful Dividend Payout only.
BCR' s 10-Year Dividend Payout Range
Min: 0.03  Med: 0.18 Max: 1.3
Current: 0.19
0.03
1.3
Dividend growth (3y) 5.10
BCR's Dividend growth (3y) is ranked lower than
67% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.10 vs. BCR: 5.10 )
Ranked among companies with meaningful Dividend growth (3y) only.
BCR' s 10-Year Dividend growth (3y) Range
Min: 3.2  Med: 5.70 Max: 7.4
Current: 5.1
3.2
7.4
Yield on cost (5-Year) 0.61
BCR's Yield on cost (5-Year) is ranked lower than
80% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.65 vs. BCR: 0.61 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BCR' s 10-Year Yield on cost (5-Year) Range
Min: 0.6  Med: 0.94 Max: 1.17
Current: 0.61
0.6
1.17
Share Buyback Rate 4.10
BCR's Share Buyback Rate is ranked higher than
94% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. BCR: 4.10 )
Ranked among companies with meaningful Share Buyback Rate only.
BCR' s 10-Year Share Buyback Rate Range
Min: 5.2  Med: 2.50 Max: -1.5
Current: 4.1

Valuation & Return

vs
industry
vs
history
Price/DCF (Earnings Based) 4.18
BCR's Price/DCF (Earnings Based) is ranked lower than
83% of the 18 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.75 vs. BCR: 4.18 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Earnings Yield (Greenblatt) (%) 4.30
BCR's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. BCR: 4.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BCR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 5.1  Med: 6.45 Max: 11
Current: 4.3
5.1
11
Forward Rate of Return (Yacktman) (%) 15.88
BCR's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 88 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.94 vs. BCR: 15.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BCR' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 6.8  Med: 18.50 Max: 23.3
Current: 15.88
6.8
23.3

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BR6.Germany,
CR Bard Inc was incorporated in New Jersey in 1923. The Company is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities The Company participates in the markets for vascular, urology, oncology and surgical specialty products. It reports its sales in four product group categories: vascular, urology, oncology and surgical specialties. The Company's vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD) and heart arrhythmias. These products include: percutaneous transluminal angioplasty, (PTA) catheters, chronic total occlusion (CTO) catheters, guidewires, fabrics, meshes, introducers and accessories; peripheral vascular stents, covered stents and vascular grafts; vena cava filters; biopsy devices; and electrophysiology products, including electrophysiology laboratory systems and diagnostic, therapeutic and temporary pacing electrode catheters. The Company's urology products include basic drainage products, continence products and urological specialty products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. These include specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters and enteral feeding devices. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs. The Company's soft tissue repair products consist of hernia repair grafts, including both synthetic and natural-tissue configurations, and hernia fixation devices. The Company competes in the therapeutic and diagnostic medical device markets around the world. Its products are distributed domestically directly to hospitals and other healthcare institutions as well as through numerous hospitals/surgical supply and other medical specialty distributors with whom the Company has distribution agreements. The Company is subject to various environmental laws and regulations both within and outside the United States.
» More Articles for BCR

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA Jul 28 2015 
Medtronic Inc. (MDT) Dividend Stock Analysis Feb 25 2015 
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis Nov 19 2014 
Weekly 52-Week Highs Highlight: LBTYK, STZ, FISV, BCR Nov 09 2014 
Dividend Aristocrats In Focus Part 19 of 54: CR Bard Oct 15 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Paulson, Mindich and Soros Bought Covidien; Should You? Sep 11 2014 
No More a Simple Distributor Sep 07 2014 

More From Other Websites
BARD C R INC /NJ/ Financials Jul 30 2015
Thermo Fisher Scientific, Inc. Earnings Analysis: By the Numbers Jul 29 2015
Edited Transcript of BCR earnings conference call or presentation 23-Jul-15 9:00pm GMT Jul 28 2015
BARD C R INC /NJ/ Files SEC form 10-Q, Quarterly Report Jul 24 2015
C.R. Bard (BCR) Beats Q2 Earnings & Revenues, Guides Up - Analyst Blog Jul 24 2015
Bard (C.R.) (BCR) Earnings Report: Q2 2015 Conference Call Transcript Jul 24 2015
Bard Announces Second Quarter Results Jul 23 2015
C R Bard Inc Earnings Call scheduled for 5:00 pm ET today Jul 23 2015
BARD C R INC /NJ/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 23 2015
C.R. Bard reports 2Q loss Jul 23 2015
C.R. Bard reports 2Q loss Jul 23 2015
Bard Announces Second Quarter Results Jul 23 2015
Q2 2015 C R Bard Inc Earnings Release - After Market Close Jul 23 2015
BARD C R INC /NJ/ Files SEC form 8-K, Other Events Jul 21 2015
Can C.R. Bard (BCR) Surprise Earnings Estimates in Q2? - Analyst Blog Jul 20 2015
Steady Eddy and his stalwart blog Jul 12 2015
Bard to Host Earnings Conference Call on July 23, 2015 Jul 01 2015
CR Bard's Lutonix DCB Proves Effective in LEVANT 2 Study - Analyst Blog Jun 26 2015
Prostate Cancer Devices Market – Trends, Forecast, and Growth Prospects Published by Technavio Jun 25 2015
The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated... Jun 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK